Bone Biologics Corporation
BBLGHealthcare|Biotechnology|US
$0.33
+0.01 (+3.00%)
DCF Value
$4.22
Tangible Book / Share
$1.59
Cash / Share
$1.63
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03810573 Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis | Degenerative Disc Disease, Spondylolisthesis | N/A | Recruiting | 30 | RCT, Double-blind | — |